Baird lowered the firm’s price target on Haemonetics (HAE) to $81 from $99 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where they lowered estimates although Plasma appears to be an upside lever.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target lowered to $80 from $90 at Mizuho
- Haemonetics price target raised to $94 from $93 at Barrington
- Haemonetics price target lowered to $75 from $88 at Citi
- Haemonetics reports Q3 adjusted EPS $1.31, consensus $1.25
- Haemonetics narrows FY26 adjusted EPS view to $4.90-$5.00 from $4.80-$5.00